5 years ago

Bit Bio Raises $41.5 Million for Human Cell Line Technology

  • Bit Bio, a Cambridge, England-based startup focused on reducing the cost and increasing the production capacity for human cell lines, has raised $41.5 million in Series A funding

  • The company's goal is to be able to reproduce every human cell type

  • Investors in the round include Richard Klausner, Foresite Capital, Blueyard Capital, and Arch Venture Partners

  • Bit Bio was founded by Mark Kotter in 2016 and is based on research building on the revolutionary discoveries of Shinya Yamanaka, which enabled scientists to transform human adult cells into embryonic stem cells.

      • ProblemBiotechnology

      "Reducing the cost and increasing the production capacity for human cell lines, which are essential for targeted gene therapies and accelerating drug discovery"

      Solution

      "Bit Bio's technology allows for the rapid and precise production of human cells, enabling the creation of pure cell lines and accelerating the development of effective treatments for various diseases"

      Covered on